On March 14, Luoxin Pharmaceuticals issued an announcement stating that its subsidiary Luoxin Anruovita Pharmaceuticals (Chengdu) Co., Ltd. received the "Drug Registration Certificate" for Levosalbutamol Hydrochloride Nebulized Inhalation Solution approved and issued by the State Drug Administration.

Levosalbutamol is a β2-adrenergic receptor agonist that can relax all airway smooth muscles from the trachea to the terminal bronchioles. Levosalbutamol Hydrochloride Nebulized Inhalation Solution is suitable for the treatment or prevention of bronchospasm caused by reversible airway obstructive diseases in adults and children over 6 years old.

The original developer of Levosalbutamol Hydrochloride Nebulized Inhalation Solution was Sepracor Inc. of the United States. It was launched in the United States in 1999 under the trade name: XOPENEX. The original formulation has not yet been imported into China. The company's salbutamol hydrochloride nebulized inhalation solution has obtained a drug registration certificate according to the new registration classification of chemical drugs, Class 3, and is deemed to have passed the consistency evaluation.

https://finance.eastmoney.com/a/202503143346252178.html